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Utility Weights for Allergic Rhinitis
Based on a Community Survey with a
Time Trade-off Technique in Japan
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ABSTRACT
Background: Allergic rhinitis is not a fatal disease, but its symptoms deteriorate the quality of life. High mor-
bidity raises a concern about its impact on health care resources. Utility weights, which are required for cost-
utility analysis by the level of severity, have not been established to date. This study aims to derive the weights
based on a community survey with a time trade-off technique.
Methods: Self-administered monthly time trade-off questionnaires were administered to representative sam-
ples in the community. Four levels of severity were defined by clinical stratification proposed in the “Practical
Guideline for the Management of Allergic Rhinitis in Japan”.
Results: 146 responses (response rate: 51.0%) were collected. Utility weights by the four levels of severity
were found to be 0.96, 0.94, 0.89 and 0.83, from mild to severest symptoms, respectively. These values were
found to be statistically independent from the respondent’s characteristics such as sex, age, existence of cur-
rent nasal symptoms or history of allergic rhinitis.
Conclusions: The authors consider that the elicited utility weights are reliable. The results of this study could
facilitate economic evaluations regarding allergic rhinitis in various contexts, contributing to better management
of the disease.
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INTRODUCTION
Allergic rhinitis has been recognised as a burden to
both health care systems and society in Europe1 and
the U.S.2 18.7% of Europeans3 and 9.9―16% of Ameri-
cans4 are estimated to be suffering from the disease.
This is similar in Japan as well. Allergic rhinitis in a
form of cedar pollinosis is one of the most common
illnesses, of which prevalence is estimated to be as
high as 19.7% of the nation.5 This means one in five
Japanese suffers allergic symptoms from winter to
spring every year, during which cedar pollens scatter
in the air. Other seasonal rhinitis caused by various
allergens and perennial allergic rhinitis also affect the
nation.6 Allergic rhinitis is not a fatal disease, but its
symptoms such as sneezing, itchy eyes or stuffy nose
deteriorate the quality of life (QOL).
The Practical Guideline for the Management of Al-
lergic Rhinitis in Japan6 was published by an expert
committee, in which clinical stratification of allergic
rhinitis symptoms and severity (Fig. 1) is clearly de-
fined for the purpose of standardization of practice
and research. Although the guideline proposes a
Japanese Rhinoconjunctivitis Quality of Life Question-
naire (JRQLQ) in order to evaluate outcomes in
terms of QOL,7 utility weights, which enable out-
comes evaluation in terms of Quality-Adjusted Life
Years (QALYs) by the level of severity of symptoms
have not been established. A utility weight is a value
from 0 to 1, which is attached to various health stat-
uses. By combining it with survival time in changing
health statuses, life expectancy is adjusted into
QALYs taking QOL into account. For example, one
year survival suffering from severe symptoms with
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Fig. 1 Clinical stratification of alergic rhinitis symptoms and severity. Source: Reference 2.
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utility weights of 0.5 is considered as an outcome
gain of 0.5 QALY. Such a calculation of QALYs with
utility weights allows a better comparison of out-
comes of QOL deteriorating disease treatments, and
it is recommended in conducting economic evalu-
ation of health care intervention.8 In Japan, 0.89 for
seasonal allergic rhinitis and 0.97 for perennial aller-
gic rhinitis as the average of patients with various lev-
els of symptoms using EQ-5D9 only was reported by
Monden and Ogino (2005)10 to date.
This paper aims to derive utility weights for allergic
rhinitis by the level of the standard clinical stratifica-
tion of severity. Since high morbidity of cedar pollino-
sis raises a concern about its impact on health care
resources in Japan11,12 and elsewhere,13,14 the results
could facilitate economic evaluations using a recom-
mended outcomes measurement, QALYs,8 which
could contribute to more efficient management of the
disease.
METHODS
In deriving utility weights, choosing whose prefer-
ence is to be elicited is essential.15 The objective of
deriving utility weights, that is, its use for cost-utility
analysis, imposes a gold standard that preference of
the general public should be elicited.16 However, util-
ity weights are sometimes drawn from patients or ex-
perts in practice, because it is often difficult for
healthy individuals to have an accurate grasp of their
health status subjected to a specific disease without
experience.17 In the context of this study, “suffering
from rhinitis” or its symptoms are both common and
easy to understand, and therefore, we choose to ask
the preference of representative samples among the
general public.
Technically, there are two approaches in eliciting
preference for health status as utility weights.18 One
approach is the use of multi-attribute health status
classification systems,19 as Monden and Ogino
(2005)9 used EQ-5D, while the other is the use of
techniques, which directly measure the preference of
individuals. We choose direct measurement in this
study, since the former approach is suitable for ques-
tioning patients. There are three most widely used
techniques in measuring preferences directly: the rat-
ing scale and its variants (RS), the standard gamble
(SG) and the time trade-off (TTO).18 RS is the easiest
and quickest to implement, but it is also known as an
erratic measure.15 Therefore, RS is often used as an
introductory or complementary to SG or TTO. Al-
though theoretical superiority of the SG against TTO
is established in regards to the axioms of the von
Neumann-Morgenstern utility theory,20 TTO is con-
sistently found much easier to respond to compared
to SG by respondents.15 Therefore, the choice be-
tween them usually depends on the context of the
study.18
In order to apply these techniques to representa-
tive samples of the general public, the mode of ques-
tioning needs to be chosen. It is known that risk or
probability communication, which is required for SG,
is better achieved by an interview along a dialogue,21
but recruiting representative interviewees from the
general public is hard to implement. On the contrary,
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Box 1 Question for TTO
Using your imagination, please answer the questions as if you are acting a role in the folowing story.  
(N.B. This is a fictional story. And no drug like this is available in real life.)
 You are about to be afected by polinosis and wil have to lead life with a certain level of discomfort for 
one month (30 days). Your symptoms wil be persistent for one month, but a brand new medicine that 
completely cures polinosis is recently developed. The pil should be taken on the first day you are 
afected.
 Yet, it has its side efects. Taking the pil relieves al symptoms of polinosis for one month, but you may 
suddenly fal asleep on a certain day after taking the medication. Then you never wake up for the rest of 
the month while the medication is efective. (The sleep is not life threatening nor harmful to your health.) 
There is no data on when you are going to fal asleep. 
 During this sleep, you wil not feel any physical change like hunger, but you are immobile and 
unconscious. After that one month of the medication, you wake-up and resume everyday activity as if 
nothing happened. (One month is assumed as 30 days.)
You have this pil now. How many healthy days do you want if you are going to take this pil? Please 
circle “Yes”or “No”in the folowing answer sheet to show the days you wish to have depending on the 
severity of symptoms. Please do not think too hard, but let us know what your intuition suggests. 
the TTO instrument can be devised as a self-
administered questionnaire,22 which can be used for
a community survey with random sampling. There-
fore, we choose the TTO complemented by the RS in
this study.
There are wide variations in designing a TTO in-
strument.23 Conventional lifetime TTO where a re-
spondent trades against unwanted premature death
originated from Torrance et al. (1976).24 The Buck-
ingham et al. (1996) experiment used two other vari-
ations: annual TTO where a respondent trades
against unwanted convalescence, and daily TTO
where a respondent trades against unwanted sleep in
a day. The use of daily TTO is most recommended
among these three, because it produces more consis-
tent results.26
We constructed our questions for the TTO (Box 1)
featuring cedar pollinosis instead of allergic rhinitis
as the disease under consideration, although the de-
scriptions of health statuses are in accordance with
the clinical stratification of allergic rhinitis symptoms
and severity. This is because featured pollinosis is
more common and therefore it could attract more at-
tention than stating allergic rhinitis. We devised a
monthly TTO taking advantage of seasonality that is
quite well-known to the general public. One month of
continuous suffering is considered easy to imagine by
the respondents. In our monthly TTO, the respon-
dent trades against unwanted sleep in a month. Un-
wanted sleep metaphor for dead status, which is simi-
lar to daily TTO employed after pilot testing was ad-
ministered to several collaborators.
Every respondent was repeatedly questioned four
times in order to fill the four separate answer sheets
(Fig. 2), imagining the sufferings of each severity
level of symptoms explained in the clinical stratifica-
tion (Fig. 1). They were asked to check ‘Yes’ or ‘No’
regarding medication according to the length of un-
wanted sleep. The level, at which answer changes
from ‘Yes’ to ‘No’, was judged as an indication of the
point of indifference in the trade-off. Utility weights
were calculated by the following formula:
Utility weight＝
30 － Number of acceptable sleeping days
30
The questionnaire starts with a face sheet on the
characteristics of the respondent, followed by an ex-
planation of clinical stratification of allergic rhinitis
symptoms and severity. Then, for each level of sever-
ity of symptoms, the respondent is asked to rate his
her preference from 0 points (dead) to 100 points
(perfect health) on the visual analogue scale. The RS
is incorporated before the TTO questions for the pur-
pose of warm-up and engaging respondents, as well
as for the comparison with the results by TTO.
The questionnaire as above was used in our com-
munity survey, of which samples were selected by
stratified systematic sampling from the basic resident
register of Tsukuba city, Ibaraki prefecture in Japan.
It is an academic and garden city located in the sub-
urbs of Tokyo. 300 samples in total were selected by
sex and age stratum of 20―39, 40―59 and 60+. Adults
of age 20 and over were chosen, since we considered
that this did not have a serious bias in the representa-
tiveness of social preference. These sex and age cate-
gories were set for the purpose of examining the reli-
ability of results. On the face sheet, existence of cur-
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Fig. 2 Instrument used for time trade-of measurement.
Are you going
to take the pill?1st day 30th day
30 healthy days/0 sleeping day
䍃䍃䍃 Yes 䍃 No
29.5 healthy days/0.5 sleeping day
䍃䍃䍃 Yes 䍃 No
29 healthy days/1 sleeping day
䍃䍃䍃 Yes 䍃 No
28 healthy days/2 sleeping days
䍃䍃䍃 Yes 䍃 No
27 healthy days/3 sleeping days
䍃䍃䍃 Yes 䍃 No
26 healthy days/4 sleeping days
䍃䍃䍃 Yes 䍃 No
25 healthy days/5 sleeping days
䍃䍃䍃 Yes 䍃 No
24 healthy days/6 sleeping days
䍃䍃䍃 Yes 䍃 No
23 healthy days/7 sleeping days
䍃䍃䍃 Yes 䍃 No
22 healthy days/8 sleeping days
䊶䊶䊶 Yes 䊶 No
21 healthy days/9 sleeping days
䊶䊶䊶 Yes 䊶 No
20 healthy days/10 sleeping days
䊶䊶䊶 Yes 䊶 No
15 healthy days/15 sleeping days
䍃䍃䍃 Yes 䍃 No
10 healthy days/20 sleeping days
䍃䍃䍃 Yes 䍃 No
5 healthy days/25 sleeping days
䍃䍃䍃 Yes 䍃 No
0 healthy day/30 sleeping days
䍃䍃䍃 Yes 䍃 No
rent nasal symptoms and history of cedar pollinosis
were also asked, so that effects of these factors on the
reliability of the results could be examined. We as-
sumed that there was no difference between allergic
rhinitis patients and non-patients regarding the un-
derstanding of suffering experiences classified in the
clinical stratification of severity. Therefore, no signifi-
cant difference was also expected between utility
weights and the history.
The questionnaire was delivered by post, followed
by the investigator visiting to collect responses at a
later date. The survey was conducted in November of
2005 when cedar pollens were not scattered in the
air.
The conduct of this study including the community
survey was approved by the research ethics commit-
tee of the Graduate School of Comprehensive Human
Sciences, University of Tsukuba.
RESULTS
Among 300 selected samples, 14 samples were un-
able to respond, because they either had been de-
ceased or relocated, which made an effective sample
size of 286. 146 responses were collected, which gave
Utility Weights for Allergic Rhinitis
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Table 1 Characteristics of respondents
N.S.＊(46.6%)68Male
Sex
(53.4%)78Female
S.†(26.7%)3920―39
Age (33.6%)4940―59
(39.7%)5860 +
(31.5%)46Yes
Curent nasal symptoms (66.4%)97No
S.( 2.1%)3No response
(33.6%)49Yes
History of cedar polinosis (63.7%)93No
( 2.7%)4No response
(SD＝11.3)12.5Average years of sufering from polinosis
＊N.S. stands for‘not significant’ ,which is found by the χ2 test.
†S. stands for‘significant’ ,which is found by the χ2 test.
Table 2 Utility weights by severity with the rating scale and time trade-of
AverageSeverestSevereModerateMildCharacteristics of respondents
Techni-
que
0.63 (0.61 0.65)0.43 (0.38 0.48)0.56 (0.52 0.60)0.71 (0.68 0.74)0.82 (0.79 0.85)＊Ratingscale
0.91 (0.89 0.92)0.83 (0.78 0.87)0.89 (0.85 0.92)0.94 (0.93 0.96)0.96 (0.95 0.97)Timetrade-of
0.89 (0.87 0.92)
N.S.†
0.80 (0.72 0.87)0.88 (0.83 0.92)0.94 (0.91 0.96)0.95 (0.94 0.97)Male
Sex
0.92 (0.90 0.94)0.85 (0.80 0.91)0.89 (0.85 0.94)0.95 (0.93 0.97)0.97 (0.95 0.98)Female
0.92 (0.89 0.94)
N.S. 
0.85 (0.79 0.92)0.91 (0.88 0.95)0.94 (0.91 0.98)0.96 (0.93 0.99)20―39
Age 0.89 (0.86 0.92)0.77 (0.67 0.87)0.87 (0.81 0.94)0.95 (0.93 0.97)0.97 (0.95 0.99)40―59
0.91 (0.89 0.93)0.86 (0.80 0.92)0.88 (0.82 0.93)0.94 (0.92 0.97)0.96 (0.94 0.98)60 +
0.92 (0.89 0.94)
N.S. 
0.83 (0.75 0.91)0.90 (0.86 0.95)0.96 (0.95 0.98)0.97 (0.95 0.99)YesCurent
nasal
symptoms 0.90 (0.88 0.92)0.82 (0.77 0.88)0.87 (0.83 0.92)0.93 (0.91 0.95)0.96 (0.94 0.97)No
0.91 (0.89 0.94)
N.S. 
0.83 (0.76 0.91)0.90 (0.86 0.95)0.95 (0.92 0.97)0.97 (0.95 0.99)YesHistory
of cedar
polinosis 0.90 (0.88 0.92)0.82 (0.77 0.88)0.88 (0.83 0.92)0.94 (0.92 0.96)0.96 (0.94 0.97)No
＊95% Confidence Interval.
†N.S. stands for‘not significant’ .Efect of characteristics of respondents is found ‘not significant’ ,tested by a generalised linear model.
a response rate of 51.0%.
Table 1 shows the characteristics of the respon-
dents. There were 68 males and 78 females. There
was no statistically significant difference in the re-
sponse rate between them by the χ2 test. 39, 49 and
58 samples responded in the age strata 20―39, 40―59
and 60+, respectively. Here, a statistically significant
difference in the response rate was found by the χ2
test. The older the age strata, the higher the re-
sponse rate. 31.5% of respondents reported currently
experiencing nasal symptoms, while 33.6% reported
having a past history of cedar pollinosis, of which av-
erage years of suffering was 12.5 years. A statistical
association was found between current nasal symp-
toms and history of cedar pollinosis by the χ2 test, de-
spite the survey being conducted during out of cedar
pollen season. This may be due to the comorbidity of
perennial allergic rhinitis or pollen allergy other than
cedar.26
Table 2 shows utility weights by severity with the
RS and TTO. Utility weights with RS by the four lev-
els of severity are 0.82, 0.71, 0.56 and 0.43 from mild
to severest symptoms, respectively, while with TTO,
0.96, 0.94, 0.89 and 0.83, respectively. Lower weights
found by RS may be due to the known tendency in
the response to RS that respondents are more in-
clined to mark the point apart from extreme ends of
the scale.15 Figure 3 illustrates these by box plots.
Tamayama K et al.
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Fig. 3 Box plots of utility weights. RS, Rating scale; TTO, Time trade-of.
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Table 2 also shows utility weights with TTO by the
characteristics of respondents. Female respondents
noted higher weights than males; respondents in age
strata 40―59 noted the lowest weights; symptomatic
respondents noted higher weights; and respondents
with history of pollinosis noted higher weights. In re-
gards to these differences, effects of characteristics of
respondents to utility weights were tested with a gen-
eralised linear model, of which result were statisti-
cally insignificant in terms of characteristics.
DISCUSSION
We elicited utility weights for allergic rhinitis by the
level of standard clinical stratification of severity de-
fined by the Practical Guideline for the Management
of Allergic Rhinitis in Japan.6 We constructed a self-
administered questionnaire applying monthly TTO
for representative samples from the community. Util-
ity weights by the four levels of severity were found
to be 0.96, 0.94, 0.89 and 0.83, from mild to severest
symptoms, respectively. The average weight of these,
0.91, can be judged as consistent with the formerly
reported 0.89 for seasonal allergic rhinitis and 0.97
for perennial allergic rhinitis in Japan, taking into ac-
count that EQ-5D was applied to patients in this study
and that seasonal rhinitis patients experience severer
symptoms than perennial rhinitis patients.9 Addition-
ally, the weights found were stable regardless of re-
spondents’ characteristics such as sex, age, current
nasal symptoms, or history of cedar pollinosis, which
allows us to consider the findings of this study as be-
ing fairly reliable for social preference.
In particular, we choose to elicit the preference of
the general public as a social preference assuming
that individuals without any history of allergic rhinitis
can imagine the various symptoms of rhinitis. If this
is not the case, there may be a difference in results
between subgroups of those with a history of allergic
rhinitis and those without it. Such a difference may
raise the problem of how to interpret these as social
preference. However, no significant differences were
found in this study.
There is a point to be noted in interpreting our re-
sults. Non-response by almost half of the samples
raises a concern about the ease of answering to our
devised self-administered TTO questionnaire. How-
ever, the response rate of 51.0% is more than the
usual response rates of mail surveys, and comparable
to those of several recent governmental interview sur-
veys, 40―50%, of which decline is considered to be
due to the citizen’s amounting awareness on privacy
backed up by the enforcement of Personal Informa-
tion Protection Act in April of 2005.27 The response
rate of 51.0% may be judged as low, but it has become
unrealistic to obtain more representative data in Ja-
pan.27 Therefore, the level of response rate of our sur-
vey can be interpreted as independent from the ease
of answering, and the questionnaire itself can be con-
sidered feasible for self-administration.
Although the clinical stratification of severity em-
ployed in this study is based on Japanese guidelines,
the description of symptoms and severities are uni-
versal enough to be used in other countries. And
found weights were not so different from 0.87, which
is reported for hay feverallergic rhinitis from the
U.S., although the severity of symptoms is not stated
in this study.28 Our results may be applicable to eco-
nomic evaluations regarding allergic rhinitis in vari-
Utility Weights for Allergic Rhinitis
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ous contexts in many countries, such as transitioning
of the second-generation antihistamines to over-the-
counter status29,30 or a tablet-based vaccination
against hay fever.31-33
We devised a monthly TTO by taking advantage of
seasonality that is quite well-known to the general
public. The monthly TTO is a new variation that is in-
between annual TTO and daily TTO, of which con-
struct validity is ensured. However, empirical com-
parison with annual TTO and daily TTO may be nec-
essary, which was not exercised in this study. This
leaves room for further study. Arnesen and Trom-
mald (2005) point out that variation in TTO questions
could undermine the comparability of QALYs across
diverse health statuses, and suggests that a detailed
description of the implemented TTO is one way to re-
lieve this problem.34 This paper transparently pre-
sents information required for comparison and dupli-
cation of technique.
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